Protocols

scPharmacuticals raises $45M B round; Struggling Nivalis and Acura take stock of “strategic alternatives”

• Lexington, MA-based scPharmaceuticals, which is taking generic drugs and reformulating them for subcutaneous injection, has raised $45.6 million in its Series B round. The round was co-led by OrbiMed and a wholly-owned subsidiary of Sun Pharmaceutical Industries, Sun Pharma. Existing investors 5AM Ventures and Lundbeckfond Ventures participated in the financing.

• A month after Nivalis $NVLS saw its shares crater after its lead program flunked a mid-stage trial, the biotech is looking at its strategic alternatives while cutting back on costs. Nivalis says it will complete its ongoing SNO-7 trial of cavosonstat in patients with CF who are currently taking Kalydeco (ivacaftor), which is expected to be completed in the first quarter of 2017.

• With its stock mired in penny territory and a market cap set at only $9 million, Acura Pharma $ACUR is scouting for strategic alternatives as well. Everything is on the table as Roth hunts for buyers.

• Affimed N.V. $AFMD inked a new collaboration with The University of Texas MD Anderson Cancer Center today, pairing Affimed’s TandAb technology in combination with MD Anderson’s natural killer cell (NK) product.


The best place to read Endpoints News? In your inbox.

Full-text daily reports for those who discover, develop, and market drugs. Join 17,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

RAPS Regulatory Convergence 2017